Controlled Release Drug Delivery Systems Market Expected To Witness A Substantial Growth Of 0.13 Billion By 2030

Posted by Mrudula Anil Karmarkar on January 7th, 2025

San Francisco, 07 January 2030: The Report Controlled Release Drug Delivery Market Size, Share & Trends Analysis Report, By Technology (Targeted Delivery, Transdermal), By Release Mechanism, By Application, By Region, And Segment Forecasts, 2023 - 2030

The global controlled release drug delivery market size is expected to reach USD 110.13 billion by 2030, registering a CAGR of 10.6% according to a new report by Grand View Research, Inc. The benefits associated with controlled release drug delivery systems such as increased therapeutic efficacy, fewer side effects, and low treatment cost are the factors driving the growth of the market during the forecast period. These technologies offer various benefits over traditional delivery forms. Reduced dosage and dosage frequency, enhanced patient compliance, less gastrointestinal side effects, uniform drug effect, improved drug efficacy and safety, and reduced fluctuation of plasma drug levels are some of the major advantages offered by controlled release technology.

The presence of multiple in-vivo biological barriers that affect the absorption, bioavailability, and stability of the drug has opened a wide horizon for controlled release drug delivery products. For instance, a controlled release drug delivery system has enabled the delivery of even large and complex molecules such as DNA/RNA, proteins, and polypeptides. Additionally, the rising awareness among healthcare professionals, regarding the advantage of controlled release drug delivery systems over conventional systems is expected to drive the demand for the market in long run.

The rapidly increasing geriatric and pediatric population is one of the major factors impacting the growth of the market. Since a major proportion of prescription non-adherence cases is observed in this age group of the population. Innovations in various drug delivery systems have been providing the geriatric and pediatric populations with easy solutions, which are further propelling the market. Controlled release of drugs allows a reduction in overdose in the elderly population as they can be altered according to the required dosage over a specific period of time.

Request sample report of Controlled Release Drug Delivery Systems Market@ https://www.grandviewresearch.com/industry-analysis/controlled-release-drug-delivery-market/request/rs1

Changing prescription pattern of physicians preferring controlled release drug delivery over conventional systems owing to the benefits such as high-therapeutic efficacy, better patient compliance, and reduced treatment cost are expected to contribute towards the growth of the market over the forecast period. Moreover, being a part of a highly competitive and fragmented market, pharmaceutical companies are pro-active with the changing market requirements and are continuously investing on developing controlled release drug delivery system, thereby significantly driving the demand.

Controlled Release Drug Delivery Market Report Highlights

• Based on application, oral controlled release systems held the largest share in the market in 2022 owing to increasing usage and ease of convenience offered for the administration of medication
• Targeted drug delivery is poised to be the fastest-growing technology segment during the forecast period owing to its various benefits such as increased therapeutic efficacy coupled with increased safety
• The osmotic delivery segment, based on activation modulation drug delivery systems, is likely to witness the highest CAGR due to its ability to not be affected by various factors, such as pH, food consumption, and gastrointestinal motility

Constantly rising R&D expenditure by pharmaceutical development companies that are focused on development of efficient therapy for chronic and non-communicable complications such as cancer, diabetes, and hypertension are expected to boost the market growth over the forecast period. For instance, Taris an R&D based biomedical company’s pipeline product TAR-200 (Gemcitabine) indicated for the treatment of bladder cancer includes a controlled release drug delivery system. Furthermore, it is expected that Johnson & Johnson will complete the acquisition of Taris Biomedical in 2020. It’s lead investigational product TAR-200 is reported to be one of the main reasons behind the acquisition.

Rising geriatric and pediatric population globally is one of the major factors contributing towards the market growth, largely due to the non-adherence to the medicine regimen as it is very common among these age-groups. Geriatric populations suffer from compromised physical, mental and biological functions that affect their medicine intake. Also, their body cannot tolerate high doses and harsh side-effects of drugs. Thus, the demand for controlled release drug delivery system is expected to grow with steeply rising patient population.

Controlled Release Drug Delivery Systems Market Report scope

Controlled release drug delivery allows significant reduction in dose and dosage frequency, prevent abnormal fluctuations of plasma drug levels, improves efficacy, enhance patient compliance and achieve uniform drug effect of the administered drug. In comparison to traditional delivery systems, the control releases drug delivery systems achieve a prolonged therapeutic effect, delivering drug at the target site at a pre-determined that too at a predictable drug release kinetics. Thus, with several added benefits offered by the controlled release delivery system, their adoption is expected to increase at a notable rate over the forecast period.